pdf

O’Melveny Represents 3D Medicines Inc. in US$52 Million Hong Kong IPO

December 15, 2022

 

FOR IMMEDIATE RELEASE

HONG KONG, DECEMBER 15, 2022 — O’Melveny recently represented 3D Medicines Inc. (1244.HK) (“3D Medicines”) in its initial public offering and listing of shares on the Main Board of the Hong Kong Stock Exchange. The IPO offering size was approximately HK$408 million (approximately US$52 million). Assuming full exercise of the over-allotment option, the offering size will be approximately HK$419 million (approximately US$54 million). O’Melveny advised 3D Medicines on both U.S. and Hong Kong laws and drafted the prospectus. This marks O’Melveny’s thirteenth Chapter 18A Hong Kong IPO completed for biotech companies, further solidifying the firm’s leading position in this field.

Founded in Shanghai in 2014, 3D Medicines is a bio-pharmaceutical company focusing on the research and development of oncology therapies for cancer patients, especially those who require long-term care. It has built a pipeline consisting of one core product and 11 drug candidates, among which, the core product envafolimab (brand name: ENWEIDA, 恩維達®), as its backbone, was approved in November 2021 and commercialized in December 2021, and seven other drug candidates are in clinical stage. Its core product envafolimab is a subcutaneously injectable PD-L1 antibody that has been approved in China for the treatment of previously treated microsatellite instability-high (MSI-H)/mismatch repair deficiency (dMMR) advanced solid tumors.

China International Capital Corporation Hong Kong Securities Limited and China Securities (International) Corporate Finance Company Limited acted as the joint sponsors for this transaction.

The O’Melveny team was led by corporate partners Ke Geng, Ke Zhu, and included counsel Qianyu Hu and Claire Huang, associates Wuxiao Liang and Cherry Ma as well as legal consultant Keren He, trainee solicitor Iris Wang and legal consultant intern Nick Mu. Associates Katherine Wang and Jingwei Huang and legal consultant Yutong Xie also provided valuable support. Partners Rob Plesnarski and Kurt Berney and counsel Billy Abbott and Dawn Lim provided tax and U.S. legal opinion related advice.

About O’Melveny

It’s more than what you do: it’s how you do it. Across sectors and borders, in board rooms and courtrooms, we measure our success by yours. And in our interactions, we commit to making your O’Melveny experience as satisfying as the outcomes we help you achieve. Our greatest accomplishment is ensuring that you never have to choose between premier lawyering and exceptional service. So, tell us. What do you want to achieve? Visit us at www.omm.com, hear what our lawyers, staff and clients have to say in Our DNA video series, or learn more in our firm at-a-glance, annual report, and on LinkedIn, Twitter, Facebook, Instagram, and YouTube.

Contact:

Shannon Lynch
O’Melveny & Myers LLP
+1 212 326 2218
slynch@omm.com

Chris Schob
O’Melveny & Myers LLP
+86 21 2307 7000
cschob@omm.com